Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective

Authors

  • Patrizia Russo Laboratory of Molecular Epidemiology, IRCCS "San Raffaele Pisana", Via di Val Cannuta, 247-249, Rome, Italy
  • Alessandra Del Bufalo Laboratory of Molecular Epidemiology, IRCCS "San Raffaele Pisana", Via di Val Cannuta, 247-249, Rome, Italy
  • Massimo Fini Scientific Direction IRCCS "San Raffaele Pisana"; Via di Val Cannuta, 247-249, Rome, Italy

DOI:

https://doi.org/10.17179/excli2014-632

Keywords:

deep-sea-derived drugs, cancer, systems medicine, network, therapy, preclinical studies, clinical studies

Abstract

The deep-sea habitat is a source of very potent marine-derived agents that may inhibit the growth of human cancer cells “in vitro” and “in vivo”. Salinosporamide-A, Marizomib, by Salinispora species is a proteasome inhibitor with promising anticancer activity (Phase I/II trials). Different deep-sea-derived drugs are under preclinical evaluation. Cancer is a complex disease that may be represented by network medicine. A simple consequence is the change of the concept of target entity from a single protein to a whole molecular pathway and or cellular network. Deep-sea-derived drugs fit well to this new concept.

Published

2015-02-10

How to Cite

Russo, P., Del Bufalo, A., & Fini, M. (2015). Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective. EXCLI Journal, 14, 228–236. https://doi.org/10.17179/excli2014-632

Issue

Section

Review articles